Graft‐versus‐Host Disease in Dog and Man: The Seattle Experience

Immunological Reviews

Volumn 88, Issue 1, 1985, Pages 215-238

  Storb, Rainer ^a,b   Thomas, E Donnall ^a,b  

^a FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ACUTE DISEASE; ALLOTRANSPLANTATION; ANIMAL; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; DOG; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; INFECTION; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; PATHOPHYSIOLOGY; REVIEW; BLOOD AND HEMOPOIETIC SYSTEM; PREVENTION; PRIORITY JOURNAL; SURVEY; T LYMPHOCYTE; THERAPY;

ACUTE DISEASE; ANIMAL; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIALS; DOGS; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMAN; INFECTION; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HOMOLOGOUS;

EID: 0022273650     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1985.tb01160.x     Document Type: Article

References (60)

1. Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft‐versus‐host disease
2. Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft‐versus‐host disease in humans
3. In vitro tests correlating with presence or absence of graft‐vs‐host disease in DLA nonidentical canine radiation chimeras: Evidence that clonal abortion maintains stable graft‐host tolerance
4. Treatment of murine leukaemia with X‐rays and homologous bone marrow
5. Marrow transplantation from related donors other than HLA‐identical siblings
6. Cellular interactions in marrow‐grafted patients. III. Normal interleukin 1 and defective interleukin 2 production in short‐term patients and in those with chronic graft‐versus‐host disease
7. Treatment of human acute graft‐versus‐host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone
8. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone mar Tow grafts from DLA‐haploidentical litter‐mates
9. Cyclosporine as prophylaxis for graft‐versus‐host disease; A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia
10. Cyclosporin A: Effect on marrow engraftment and graft‐versus‐host disease in dogs
11. Cyclosporin A and methotrexate in canine marrow transplantation: Engraftment, graft‐versus‐host disease, and Induction of tolerance
12. Treatment of graft‐versus‐host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids
13. Failure of early administration of antithymocyte globulin to lessen graft‐versus‐host disease in human allogeneic marrow transplant recipients
14. Cytotoxic typing antisera for marrow grafting in littermate dogs
15. Mortality of secondary disease in antibiotic‐treated mouse radiation chimeras
16. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras
17. Treatment of acute graft‐versus‐host disease after allogeneic marrow transplantation: A randomized study comparing corticosteroids and cyclosporine
18. Lethal GvHD across minor histocompatibility barriers: Nature of the effector cells and role of the H‐2 complex
19. Incidence of acute graft‐versus‐host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients
20. Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation
21. Effects of in vitro depletion of T cells in HLA‐identical allogeneic marrow grafts
22. Preincubation of donor bone marrow cells with a combination of murine monoclonal anti‐T‐cell antibodies without complement does not prevent graft‐versus‐host disease after allogeneic marrow transplantation
23. Adoptive immunotherapy of acute leukemia: Experimental and clinical results
24. Infection in bone marrow transplantation
25. Cellular interactions in marrow‐grafted patients. I. Impairment of cell‐mediated lympholysis associated with graft‐vs‐host disease and the effect of interleukin 2
26. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants
27. Murine monoclonal anti‐T cell antibodies for treatment of steroid‐resistant acute graft‐versus‐host disease
28. Efficacy of short course (four dose) methotrexate following bone marrow transplantation for prevention of graft‐vs‐host disease
29. Pathophysiology and prevention of graft‐versus‐host disease
30. Marrow transplantation for chronic myelocytic leukemia: A controlled trial of cyclosporine versus methotrexate for prophylaxis of graft‐versus‐host disease
31. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients
32. Methotrexate regimens for control of graft‐versus‐host disease In dogs with allogeneic marrow grafts
33. Treatment of established human graft‐versus‐host disease by antithymocyte globulin
34. Treatment of established graft‐versus‐host disease in dogs by antithymocyte serum or prednisone
35. Graft‐versus‐host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA‐identical siblings. Beneficial effect of a protective environment
36. An association between HLA‐B antigens and acute graft‐versus‐host disease
37. Predictive factors in chronic graft‐versus‐host disease in patients with aplastic anemia treated by marrow transplantation from HLA‐identical siblings
38. Marrow grafts between DL‐A‐matched canine littermates
39. Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture
40. Marrow grafts between DLA‐identical and homozygous unrelated dogs: Evidence for an additional locus involved in graft‐versus‐host disease
41. Antileukemic effect of high dose fractionated total body irradiation (TBI) and manipulation of graft‐vs‐host disease (GvHD) immunosuppression following bone marrow transplantation (BMT)
42. Late complications after marrow transplantation
43. The pathophysiology and treatment of graft‐versus‐host disease
44. Chronic graft‐versus‐host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
45. Biology and treatment of chronic graft‐versus‐host disease
46. Bone‐marrow transplantation
47. Nonspecific suppressor cells in patients with chronic graft‐vs‐host disease after marrow grafting
48. Cell‐mediated immunity to non‐HLA antigens of the host by donor lymphocytes in patients with chronic graft‐vs‐host disease
49. Specific suppressor cells in graft‐host tolerance of HLA‐identical marrow transplantation
50. Anti‐host cytotoxic cells in patients with acute graft‐versus‐host disease after HLA‐identical marrow grafting
51. Role of bacterial microflora in development of intestinal lesions from graft‐versus‐host reaction
52. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora
53. Antihuman thymocyte globulin for prophylaxis of graft‐versus‐host disease. A randomized trial in patients with leukemia treated with HLA‐identical sibling marrow grafts
54. Antileukemic effect of graft‐versus‐host disease in human recipients of allogeneic‐marrow grafts
55. Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance
56. Antileukemic effect of chronic graft‐versus‐host disease. Contribution to improved survival after allogeneic marrow transplantation
57. Thymosin fraction 5 does not accelerate reconstitution of immunologic reactivity after human marrow grafting
58. Immunologic reconstitution after human marrow grafting